Considerations for Selection of a CDMO to Reproducibly Manufacture a Low Endotoxin Antisense Oligonucleotide for Intrathecal Injection
Time: 2:00 pm
day: Conference Day Two
Details:
- Managing analytical/process development and manufacturing virtually
- Sources of endotoxin introduction and facility/equipment/process designs to reproducibly control to low endotoxin thresholds
- How your IT bolus and dosing strategy will define DS and DP endotoxin specifications at your CDMO
